Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure

被引:22
|
作者
Cohen, DS [1 ]
Mathis, JE [1 ]
Dotson, RA [1 ]
Graybill, SR [1 ]
Wosu, NJ [1 ]
机构
[1] Novartis Pharmaceut Corp, Dept Cardiovasc Pharmacol, Summit, NJ 07901 USA
关键词
angiotensin-converting enzyme inhibition; neutral endopeptidase inhibition; remnant kidney; reduced renal mass;
D O I
10.1097/00005344-199807000-00014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of these studies was to compare the effects of CGS 30440 (CGS), a dual angiotensin-converting enzyme inhibitor (ACEI)/neutral endopeptidase inhibitor (NEPI) to benazepril (BZ), an ACEI, in a model of five-sixths nephrectomy. The doses of BZ and CGS 30440 tested were 6.5 mu mol/kg/day and 2.2 mu mol/kg/day. Drugs or vehicle (V) were administered subcutaneously for 6 weeks with dosing initiated 1 week after renal mass reduction. At 6 weeks or receiving drug (7 weeks after five-sixths nephrectomy), CGS/6.5 and BZ/6.5 and CGS/2.2 maintained systolic blood pressures (SBP) at presurgical values. BZ/2.2 did not reduce SEP and was similar to the V group. Urinary protein excretion increased > 10-fold in the V-treated group. BZ, at either dose, reduced the proteinuria slightly. CGS/6.5 and CGS/2.2 caused significant (p < 0.05) reductions in proteinuria. Creatinine clearance (Cr-cl), was reduced by 82% in V, 65 and 61% in the CGS/6.5 and CGS/2.2 groups, and by 69 and 74% in the BZ/6.5 and BZ/2.2 groups, respectively. Both CGS treatments improved the fractional excretion of Naf (%FENa) significantly from the BZ and V groups. The %FENa for BZ at either dose did not differ from that of V. Elevated urinary cyclic guanosine monophosphate (cGMP), an indicator suggesting increased intrarenal levels of atrial natriuretic peptide (ANP), was observed only in the CGS groups. Histologic examination indicated that BZ/6.5 reduced glomerular sclerosis and the extent of tubular dilation, whereas BZ/2.2 had little effect. CGS, especially at the high dose, virtually normalized the glomerular and tubular pathology. Compared with BZ, CGS 30440 treatment further diminished tubular dilation and proteinaceous cast formation. These tubular effects are consistent with some of the renal actions of ANP. The results from these studies indicate that CGS 30440, a combined ACEI/NEPI, conferred a greater renal protective effect than did ACE inhibition alone. Key Words: Angiotensin-converting enzyme inhibition-Neutral endopeptidase inhibition-Remnant kidney-Reduced renal mass.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 50 条
  • [21] Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men
    Regamey, F
    Maillard, M
    Nussberger, R
    Brunner, HR
    Burnier, M
    HYPERTENSION, 2002, 40 (03) : 266 - 272
  • [22] PRESERVATION OF RENAL-FUNCTION IN A MODEL OF CHRONIC-RENAL-FAILURE - THE EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION (ACEI) VS NEUTRAL ENDOPEPTIDASE INHIBITION (NEPI)
    MATHIS, JE
    DOTSON, RA
    GRAYBILL, SC
    HSU, HH
    COHEN, DS
    FASEB JOURNAL, 1995, 9 (04): : A686 - A686
  • [23] Administration of angiotensin-converting enzyme inhibitor and oral adsorbent in rats with established chronic renal failure.
    Shibahara, H
    Okada, K
    Takahashi, S
    Kanmatsuse, K
    Sugino, N
    Shimamura, T
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3088 - A3088
  • [24] COMBINED INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN-CONVERTING ENZYME IN CARDIOMYOPATHIC HAMSTERS WITH COMPENSATED HEART-FAILURE
    TRIPPODO, NC
    FOX, M
    NATARAJAN, V
    PANCHAL, BC
    DORSO, CR
    ASAAD, MM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1993, 267 (01): : 108 - 116
  • [25] CHARACTERIZATION OF A DUAL INHIBITOR OF ANGIOTENSIN I-CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE
    FRENCH, JF
    FLYNN, GA
    GIROUX, EL
    MEHDI, S
    ANDERSON, B
    BEACH, DC
    KOEHL, JR
    DAGE, RC
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 268 (01): : 180 - 186
  • [26] Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure
    Struckman, DR
    Rivey, MP
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (02) : 242 - 248
  • [27] In vivo inhibition of angiotensin converting enzyme and neutral endopeptidase by a dual vasopeptidase inhibitor
    Burrell, LM
    Rockell, MD
    Powell, J
    Johnston, CI
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 119A - 119A
  • [28] Vascular protective effects of combined therapy of angiotensin receptor blocker and angiotensin-converting enzyme inhibitor in essential hypertension.
    Morimoto, Satoshi
    Tokoro, Toshiko
    Kikuchi, Sanae
    Yamahara, Hideki
    Imada, Takanobu
    Kohno, Keiko
    Masaki, Hiroya
    Takahashi, Nobuyuki
    Nishikawa, Mitsushige
    Iwasaka, Toshiji
    JOURNAL OF HYPERTENSION, 2006, 24 : 190 - 190
  • [29] ANGIOTENSIN-CONVERTING ENZYME INHIBITOR ANGIOEDEMA
    Bolton, Michaelina R.
    Dooley-Hash, Suzanne L.
    JOURNAL OF EMERGENCY MEDICINE, 2012, 43 (04): : E261 - E262
  • [30] CARDIAC AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR TREATMENT IN THE RENAL ABLATION MODEL
    FABRIS, B
    FISCHETTI, F
    CARRETTA, R
    NARDUCCI, P
    PICCININI, C
    CALCI, M
    BIAGI, A
    CANDIDO, R
    BARDELLI, M
    CAMPANACCI, L
    JOURNAL OF HYPERTENSION, 1993, 11 : S344 - S345